JPRN-jRCT2031230364招募中3 期
A Single-blind, Randomized, Controlled, Parallel-group, Comparative Study Evaluating the Safety and Effectiveness of VER-01 as an Adjunct to Sealing Sutured Cranial Dural Repair
Deura Imari0 个研究点目标入组 130 人开始时间: 2023年9月27日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Pre-operative
- •1.Subjects undergoing an elective craniotomy or decompressive craniectomy surgery in supratentorial or posterior fossa
- •2.At least 18 years of age at the time of informed consent.
- •3.Willingness to comply with the protocol.
- •4.Willingness to give consent before all study-related activities.
- •Intra-operative
- •1.Surgical wound classification Class I. Superficial penetration of mastoid air cells during partial mastoidectomy is permitted.
- •2.The cuff of native dura along the craniotomy edge on each side is adequate, based on judgement of principal investigator or sub-investigator, to facilitate suturing and to allow for sufficient surface area for adherence of the sealant
- •3.Presence of intra-operative spontaneous cerebrospinal fluid (CSF) leakage following sutured dural closure or after Valsalva maneuver. If a spontaneous leak is apparent immediately after dural closure, no Valsalva maneuver will be performed.
排除标准
- •Pre-operative
- •1.Subjects with a cranial dural lesion from a recent surgery that still has the potential for CSF leakage.
- •2.Chemotherapy scheduled within 30 days prior to enrollment or scheduled within 7 days following surgery.
- •3.Radiation therapy to the head scheduled within 30 days prior to enrollment or scheduled within 7 days following surgery.
- •4.Corticosteroids on a chronic basis (more than 6 weeks) unless treatment is discontinued 4 weeks prior to planned surgery
- •5.Subjects who have intolerance to any of the components of the investigational or comparator products (including bovine-derived ingredients).
- •6.Subjects who are not willing to use blood products.
- •7.Subjects with any other pre-operative finding identified by the surgeon that in their opinion, may affect the primary or secondary endpoints such as severely altered renal or hepatic function, compromised immune system, autoimmune disease or uncontrolled/poorly controlled diabetes with the risk of wound healing complication.
- •8.Subjects who have hydrocephalus (unless hydrocephalus caused by posterior fossa pathology or incompletely open cerebrospinal fluid pathways is treated in this study)
- •9.Subjects with traumatic injuries to the head with damage to the dura and/or with an existing shunt or drain for decompression.
- •10.Subjects of childbearing potential with a positive pregnancy test or those who intend to become pregnant during the clinical study period.
- •11.Subjects who are breastfeeding.
- •12.Subjects who have participated in or will participate in another clinical trial of another a test drug/device within 30 days of a surgery of the clinical trial.
- •13.Subjects judged to be inappropriate by the principal investigator or sub-investigator.
- •Intra-operative
- •1.Unintentional dural tears during craniotomy/ decompressive craniectomy that cannot be suture repaired.
- •2.Subject has a gap between durotomy edges of greater than 2 mm after primary dural closure.
- •3.Use of implants made of synthetic materials that cannot be sutured to dura, shunts, ventricular and subdural drains.
- •4.Intersecting durotomy scars in the surgical path from a previous operation that cannot be completely removed by the planned dural resection.
- •5.Placement of Gliadel Wafers
- •6.Two or more separate dural defects.
- •7.Subjects who have serious complication in surgeries requiring emergency resuscitation or changing of planned surgeries.
- •8.Subjects judged to be inappropriate by the principal investigator or sub-investigator.
研究者
相似试验
招募中
3 期
VER-01 Hemostasis in Cardiovascular Surgery StudyJPRN-jRCT2031230363Deura Imari160
已完成
不适用
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease INTRUST1-J449 Chronic obstructive pulmonary disease, unspecifiedChronic obstructive pulmonary disease, unspecifiedJ449PER-049-09OVARTIS BIOSCIENSES PERU S.A.,
进行中（未招募）
1 期
This is a Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10, Rituxan and MabThera in Patients with Rheumatoid ArthritisMedDRA version: 16.1Level: HLTClassification code 10039075Term: Rheumatoid arthritis and associated conditionsSystem Organ Class: 100000004870Rheumatoid ArthritisEUCTR2013-004555-21-LVCELLTRION, Inc.361
进行中（未招募）
1 期
This is a Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10, Rituxan and MabThera in Patients with Rheumatoid ArthritisRheumatoid ArthritisMedDRA version: 20.0Level: HLTClassification code 10039075Term: Rheumatoid arthritis and associated conditionsSystem Organ Class: 100000004870EUCTR2013-004555-21-DECELLTRION, Inc.372
进行中（未招募）
1 期
This is a Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10, Rituxan and MabThera in Patients with Rheumatoid ArthritisMedDRA version: 16.1Level: HLTClassification code 10039075Term: Rheumatoid arthritis and associated conditionsSystem Organ Class: 100000004870Rheumatoid ArthritisEUCTR2013-004555-21-GRCELLTRION, Inc.361